Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TAK-981 plus pembrolizumab in advanced solid tumors
NCT04381650Phase 2Completed
- Sponsor
- Takeda
- Start
- Aug 2020
- Primary completion
- Oct 2024
- Modality
- Small Molecules
- Countries
- 9
01
Overview
Phase 2, open-label trial of subasumstat in non-small cell lung cancer (NSCLC), Cervical Cancer (CC), colorectal cancer (CRC) and 1 more (11 arms), sponsored by Takeda. Primary endpoints: Treatment Emergent Adverse Events at 24 months, Dose Limiting Toxicities and 5 more. Started Aug 2020; status: completed.
02
Drugs
subasumstat
03
Conditions
non-small cell lung cancer (NSCLC)Cervical Cancer (CC)colorectal cancer (CRC)melanoma
Beyond the preview
Go deeper on NCT04381650.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04381650.